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Objectives: Invasive fungal infections (IFIs) contribute signiﬁcantly to mortality and morbidity in patients
receiving myelosuppressive chemotherapy for haematological malignancies. The present study investigates
the overall survival (OS), infection-related mortality and changes in treatment of IFIs in our department
from 1995 until 2006.
Methods: Outcomes of all chemotherapy courses were retrospectively evaluated using a standard question-
naire. Modiﬁed EORTC/MSG criteria for IFIs were applied: a positive PCR result for Aspergillus spp. in bronchoal-
veolar lavage was also deﬁned as probable IFI.
Results: In total, 1693 chemotherapy courses in 592 patients were evaluated. Sixty-three percent of
chemotherapy courses were given to treat acute myeloid leukaemia, with the rest for acute lymphoblastic
leukaemia or aggressive lymphoma. IFIs were observed in 139/592 patients [23.5%, 95% conﬁdence interval
(CI) 20%–27%] and in 149/1693 courses (8.8%, 95% CI 8%–10%). IFI-related mortality was 56.9% in
1995–2001 and 28.6% in 2002–06, P,0.001. Accordingly, median OS in patients with IFI increased: 54 days
(95% CI 26–82 days) in 1995–2001 versus 229 days (95% CI 35–423 days) in 2002–06, P¼0.001. By multi-
variate analysis, factors predictive for better OS were controlled disease after chemotherapy [hazard ratio (HR)
0.228, P,0.001], possible IFI (in contrast to proven/probable IFI, HR 0.537, P¼0.005), age ,60 years (HR
0.583, P¼0.008), time period 2002–06 (HR 0.612, P¼0.021) and use of novel antifungals (HR 0.589, P¼0.033).
Conclusions: Compared with 1995–2001, IFI-related mortality decreased and OS in patients with IFI increased
signiﬁcantly in recent years. Improved OS was associated with controlled haematological disease, certainty of IFI
diagnosis (possible), younger age, time period 2002–06 and the use of novel antifungals.
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Introduction
Invasive fungal infections (IFIs) are a leading cause of mortality
and morbidity in patients with haematological malignancies and
prolonged neutropenia after chemotherapy.
1–3The prevalence of
IFI ranges from 2% to 40%, depending upon a variety of factors,
including the underlying disease and required treatment.
4–6 In
patients with febrile neutropenia as well as in autopsies from
patients with haematological malignancies, incidences of 13%–
21% have beenreported.
7,8Othersdeducea muchhigher infection
rate from the fact that 60% of patients with pulmonary inﬁltrates
respond to antimycotic treatment, whereas only 30% respond to
antibiotics alone.
9 In haematological malignancies, the most
common manifestation of IFI is fungal pneumonia, often caused
by moulds such as Aspergillus species.
10
It has been shown that patients with pulmonary inﬁltrates in
their neutropenic phase have a much worse prognosis than
those without.
11 This is why empirical and pre-emptive
antimycotic treatment in persistently febrile neutropenic patients
have become well-recognized parts of current treatment
strategies.
12,13
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761Amphotericin B has been the gold standard for the treatment
of IFI for many years. However, this treatment is associated with
a considerable toxicity, particularly regarding renal function.
14
Newer antimycotic drugs with better tolerability, such as
echinocandins and azoles, can be regarded as alternatives to
amphotericin B.
15,16 Although it is widely accepted that these
drugs have a considerably favourable toxicity proﬁle compared
with conventional amphotericin B, it is as yet unknown if the
use of the newer antifungal agents has an inﬂuence on overall
survival (OS) or fungal infection-related mortality. At least for
some haematological malignancies a clear survival beneﬁt
due to improved supportive care has been shown in the past,
17
but epidemiological studies investigating the effects of novel
antifungals in patients with acute leukaemia who did not
undergo allogeneic transplantation are lacking.
In our department (tertiary care centre, University of Bonn),
all patients with acute leukaemia were treated on the same
ward. Antileukaemic treatment has not changed signiﬁcantly
during the past 12 years and comprehensive diagnostic pro-
cedures have been performed in patients with febrile neutrope-
nia since 1995. In this uniform setting, we evaluated the
incidence of IFI as well as IFI-related mortality and OS in patients
with IFI, and analysed time trends in IFI-related mortality.
Patients and methods
A retrospective cohort study was performed in all patients treated with
myelosuppressive chemotherapy for haematological malignancies or
autologous stem cell transplantation (SCT) at a tertiary care centre (Uni-
versity of Bonn, Germany) from 1995 to 2006. Data of chemotherapy
courses were collected with a standard questionnaire. For episodes with
occurrence of proven, probable or possible IFI, an additional validated
and tested structured questionnaire was implemented to document
data of medical records, imaging reports, histopathology reports, micro-
biological reports and use of antifungal agents. All applied chemotherapy
courses were documented, except for courses given for palliative treat-
ment, intrathecal therapy or courses with cyclophosphamide given for
stem cell harvest. The pre-planned criteria for diagnosis of IFI were
based on the 2002 version of the European Organization for Research
and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria.
18
To ensure comparability with previously published data, the criteria were
not adapted to the revised EORTC/MSG criteria published in 2008.
19 In
addition to these criteria, a positive PCR for Aspergillus spp. in bronchoal-
veolar lavage (BAL) was also deﬁned as probable IFI. Documentation
and data entry were performed by different persons; a data check was
done during this process. The last follow-up data for patients with IFI
were collected in July 2008.
Treatment and prophylaxis protocols
All patients were treated according to standard protocols of multicentric
German study groups, i.e. the German Multicentre Study Group on Adult
Acute Lymphoblastic Leukaemia (GMALL) protocol was applied in patients
withacutelymphoblasticleukaemia(ALL),andtheAMLCooperativeGroup
(AMLCG)(1995–97)andAMLStudyGroup(AMLSG)(1998–2006)protocols
were applied for the treatment of acute myeloid leukaemia (AML).
20,21
Antimicrobial prophylaxis consisted of colistin, co-trimoxazole and oral
amphotericin B (in patients with ALL) or itraconazole (in patients with
AML as described by Glasmacher et al.
22).
Conventional amphotericin B as primary antifungal therapy was rou-
tinely administered throughout the whole observation period. If patients
presented with clinically signiﬁcant renal insufﬁciency they were treated
with liposomal amphotericin B. Since 1999, novel antifungal agents
were increasingly used in these patients. Intravenous itraconazole was
introduced in 1999, but was given only occasionally due to oral itracona-
zole prophylaxis in most patients. Caspofungin was used in clinical trials
from 1999 to 2003 and routinely from 2002 onwards. Use of voricona-
zole started in 2003.
At the onset of fever, blood cultures and a chest radiograph were per-
formed. If pulmonary inﬁltrates were seen or antibiotic refractory fever
lasted for .72 h, a computer tomography (CT) was done to identify sus-
pected fungal infection. From 2000 onwards, blood samples were col-
lected twice weekly as routine to detect the galactomannan antigen
using the Platelia Aspergillus galactomannan enzyme-linked immuno-
assay.
23 Panfungal PCR from BAL
24 was applied in individual cases in
2001. In 2002, this changed to routine practice whenever a broncho-
scopy could be done. Renal dysfunction was deﬁned as serum creatinine
above the upper limit of normal (ULN). Hepatic dysfunction was deﬁned
as bilirubin or alanine aminotransferase or aspartate transaminase
above the ULN. IFI-related death was deﬁned as death with continuing
signs of IFI.
Statistical analysis
According to a pre-speciﬁed analysis plan, two cohorts of patients were
deﬁned: patients diagnosed with IFI from 1995 to 2001 and from 2002
to 2006. This year was selected in advance because of a change in diag-
nostic practice (Aspergillus galactomannan test, PCR) and availability of
novel antifungal agents (caspofungin, voriconazole).
Fisher’s exact, x
2 and Mann–Whitney tests were used to test for
differences where appropriate. Survival was analysed using the
Kaplan–Meier method and the log-rank test was used to test for differ-
ences. A two-sided P value of ,0.05 was considered statistically signiﬁ-
cant. OS was calculated from the day of start of chemotherapy to the
date of death or last follow-up. The multivariate Cox regression model
was used to analyse risk factors for death. Variables with P values of
,0.1 in univariate analysis and less than or equal to three missing
values were entered in backward stepwise selection models, and
hazard ratios (HRs) with 95% conﬁdence intervals (CIs) are reported.
Statistical analyses were performed by SPSS v. 17 (Munich, Germany).
The 95% CIs were calculated with GraphPad InStat V2.05.
Results
Study population
All 1693 chemotherapy courses from 592 patients were included
in the analysis. Data were incomplete in 23/1693 courses (1.4%).
The number of courses per year ranged between 83 and 195.
Baseline characteristics of courses and patients are given
in Table 1. Standard intensive chemotherapy was given in
1142/1693 courses (67.5%), high-dose cytarabine in 404
courses (23.9%) and autologous SCT in 147 courses (8.7%). In
1433/1693 courses (84.6%) the patients were neutropenic
(leucocytes,1.0/nL or neutrophils,0.5/nL), with a duration of
 10 days in 1085/1693 courses (64.1%).
In 1117/1693 courses (66.0%) at least one febrile episode
occurred. Fever of unknown origin was present in 533/1693
courses (31.5%), pneumonia in 341 (20.1%), microbiologically
documented infection in 401 (23.7%) and other clinically docu-
mented infection in 119 (7.0%). Antifungal therapy had been
applied in 381/1693 courses (22.5%). In-hospital death occurred
in 214/592 patients (36.1%). Main reasons of death were infec-
tion in 154/214 patients (72%) and underlying disease in 27/
214 patients (12.6%).
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The total number of chemotherapy courses in which an IFI
occurred was 149/1693 (8.8%, 95% CI 8%–10%). Seventy-ﬁve
IFIs were classiﬁed as possible (4.4%), 32 as probable (1.9%)
and 42 as proven (2.5%). Proven IFI was pulmonary IFI in 16/42
(38.1%) and fungaemia in 20/42 (47.6%) courses. The remaining
proven infections included tissue infections of multiple organs
(three patients), tissue infections of other organs (two patients)
and pulmonary IFI combined with fungaemia (one patient).
Median time to IFI was 18 days after the start of chemother-
apy (interquartile range 13–26 days). Systemic antifungal pro-
phylaxis had been administered in 128/149 courses (85.9%)
with IFI and in most cases itraconazole was given [119/149
(79.9%)]. The reason to start antifungal therapy was empirical
therapy (i.e. absence of radiological ﬁndings) in 31/149 courses
(20.8%) and deﬁnite therapy in 114/149 courses (76.5%). Four
patients did not receive antifungal therapy.
Patients received a median of two antifungal agents for a
median treatment duration of 17 days (interquartile range 11–
27 days). Combination therapy had been given in 29/149
courses (19.5%), and 15 of these included caspofungin and/or
voriconazole. Conventional amphotericin B had been adminis-
tered as mono or combination therapy in 124 courses (83.2%),
liposomal amphotericin B in 13 courses (8.7%), amphotericin B
lipid complex in 5 courses (3.4%), ﬂucytosine in 10 courses
(6.7%), ﬂuconazole in 6 courses (4.0%), itraconazole in 26
courses (17.4%), voriconazole in11 courses (7.4%)and caspofun-
gin in 48 courses (32.2%). The success rate with conventional
amphotericin B was 42/124 (33.9%, 95% CI 26%–43%), with
amphotericin B lipid formulations was 6/18 (33.3%, 95% CI
13%–59%), with itraconazole was 9/26 (34.6%, 95% CI 17%–
56%), with voriconazole was 6/11 (54.5%, 95% CI 23%–83%)
and with caspofungin was 30/48 (62.5%, 95% CI 47%–76%).
IFI-related death occurred in 61/149 courses (40.9%). In-hospital
deathratewassigniﬁcantlyhigherinpatientswithIFIthanincon-
trols (58/149, 38.9% versus 156/1544, 10.1%, P,0.001). Seven-
teen patients (11.4%) suffered a further IFI and 10 of these
were in our hospital. OS analysis was performed on a patient-
based dataset (N¼139). Patients with second episodes of IFI
were not censored at the time of the second IFI. Median OS for
patientswithIFIwas148 days(95%CI93–203 days),withsigniﬁ-
cant differences for patients with proven, probable or possible IFI
(Figure 1): 56 days (95% CI 22–90 days) in proven IFI compared
with 138 days (95% CI 0–360 days) in probable and 209 days
(95% CI 93–325 days) in possible IFI (P¼0.024).
Comparison of the two time periods (1995–2001
versus 2002–06)
When analysing all courses, no differences between the two time
periods could be observed regarding dose intensity of che-
motherapy (standard, high-dose cytarabine, autologous SCT),
duration of neutropenia, neutropenia 10 days, controlled
underlying disease (complete or partial remission) before or
after chemotherapy and incidence of pneumonia. In-hospital
death was signiﬁcantly lower in 2002–06 (83/774 courses,
10.7%, 95% CI 9%–13% versus 131/919, 14.3%, 95% CI
12%–17% in 1995–2001, P¼0.033), whereas the incidence of
IFI was signiﬁcantly higher. From 1995 to 2001, an IFI occurred
in 65/919 courses (7.1%, 95% CI 5%–9%) as opposed to 84/774
courses (10.9%, 95% CI 9%–13%) with IFI from 2002 to 2006,
P¼0.007.
A comparison of variables in courses with IFI in the two
time periods is given in Table 2. A signiﬁcant difference was
detected for incidence of proven and probable IFI (P¼0.006
and P,0.001, respectively), reason for antifungal treatment
(P¼0.001),mediantimetoIFItreatmentfromdayofIFIdiagnosis
(P¼0.047) and overall change in antifungal treatment regime
from 2002 onwards, i.e. less frequent use of amphotericin B
(P¼0.001) and increased use of caspofungin (P,0.001) and
voriconazole (P¼0.003). Interestingly, a reduction in IFI-related
mortality could be found: 37/65 courses with IFI (56.9%, 95% CI
44%–69%) had a fatal outcome in 1995–2001 versus 24/84
courses (28.6%, 95% CI 19%–39%) in 2002–06, P¼0.001. The
same result was obtained if IFI-related mortality was analysed
per patient (only the ﬁrst episode analysed): death with
continuing signs of IFI was observed in 35/61 patients (57.4%,
95% CI 44%–70%) before 2002 versus 22/78 patients (28.2%,
95%CI19%–40%)intheperiod2002–06,P¼0.001.Anincreased
OS in patients with IFI could be demonstrated for the time period
2002–06 (Figure 2, patient-based analysis, N¼139). Median OS
was 54 days (95% CI 26–82 days) before 2002 versus 229 days
(95% CI 35–423 days) for the period from 2002 onwards,
P¼0.001.
No differences between the two time periods in courses with
IFI could be shown for age, duration of neutropenia, patients
with AML, controlled disease before or after chemotherapy, sys-
temic antimycotic prophylaxis, dose intensity of chemotherapy,
Table 1. Baseline characteristics of courses and patients
Characteristic
Courses
(N¼1693)
Patients
(N¼592)
a
Median age (years, min.–max.) 57 (17–82) 59 (17–81)
Male sex (n, %) 976 (57.6%) 350 (59.1%)
Diagnosis (n,% )
AML 1071 (63.3%) 408 (68.9%)
ALL/B-ALL/B-NHL 504 (29.8%) 109 (18.4%)
others 118 (7.0%) 75 (12.7%)
Status before chemotherapy (n,% )
newly diagnosed 514 (30.4%) 476 (80.4%)
complete/partial remission 905 (53.5%) 82 (13.9%)
relapse 158 (9.3%) 25 (4.2%)
refractory 116 (6.9%) 9 (1.5%)
Concomitant disease (n,% )
cardiovascular 261 (15.4%) 107 (18.1%)
pulmonary 265 (15.7%) 73 (12.3%)
Duration of neutropenia (days,
interquartile range)
13 (6–20) 15 (8–20)
AML, acute myeloid leukaemia; B-ALL, B-cell acute lymphoblastic
leukaemia; B-NHL, B-cell non-Hodgkin lymphoma.
aOnly the ﬁrst course of each patient in the database was analysed;
median number of courses per patient¼2.
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JACfungaemia/tissue infection, pathogens in proven IFI and hepatic
or renal dysfunction before start of antifungal treatment.
Multivariate analysis for OS in patients
with IFI
More than 20 variables that might have an inﬂuence on OS in
patients with IFI were tested in univariate analysis, i.e.
age, sex, underlying disease, kind of chemotherapy, status of
haematological disease before and after chemotherapy, dur-
ation of neutropenia, concomitant diseases, renal and/or
hepatic dysfunction, year of IFI diagnosis, classiﬁcation, and
treatment of IFI. The following factors had a signiﬁcant inﬂuence
on OS (P,0.1): age ,60 years; controlled disease before che-
motherapy; controlled disease after chemotherapy; proven IFI;
possible IFI; therapy with novel antifungal agents (i.e. caspofun-
gin and/or voriconazole); and time period (1995–2001 versus
2002–06). Including all these variables in a multivariate Cox
regression analysis, controlled disease after chemotherapy (HR
0.228, 95% CI 0.149–0.351, P,0.001), classiﬁcation as possible
IFI (HR 0.537, 95% CI 0.349–0.828, P¼0.005), age ,60 years
(HR 0.583, 95% CI 0.392–0.869, P¼0.008), time period 2002–
06 (HR 0.612, 95% CI 0.403–0.930, P¼0.021) and use of novel
antifungal agents (HR 0.589, 95% CI 0.362–0.959, P¼0.033)
were associated with signiﬁcantly improved OS (Table 3).
Discussion
In our study of a large consecutive single-centre cohort of
patients in whom treatment of underlying disease and prophy-
laxis strategy did not change over 12 years, we could show
that the detection rate of IFI increased, whereas IFI-related mor-
tality decreased and OS in patients with IFI increased during the
years 2002–06. We also identiﬁed factors inﬂuencing OS in
patients with IFI. By multivariate analysis, controlled disease
after chemotherapy, classiﬁcation as possible IFI (in contrast
to diagnosis of probable or proven IFI), age ,60 years, time
period 2002–06 and use of novel antifungal agents were signiﬁ-
cantly associated with improved OS. Because there is collinearity
between the time period and the use of novel antifungal agents,
which might have an impact on multivariate analysis, we
repeated the analysis and excluded the time period from the
Cox regression model. In this second model (data not shown),
all previously signiﬁcant variables remained signiﬁcant as inde-
pendent prognostic factors.
Whereas antileukaemic treatment has not changed signiﬁ-
cantly during the past 10 years, supportive therapy has improved
considerably.
17 With the approval of newer azoles as well as
echinocandins, alternatives to amphotericin B, its lipid formu-
lations or pyrimidine derivates have become available. In our
multivariate analysis, we show for the ﬁrst time that in patients
with haematological malignancies and myelosuppressive
chemotherapy or autologous SCT, the use of novel antifungal
agents was an independent factor for improved OS in patients
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Figure 1. Overall survival (years) since start of chemotherapy in patients with proven, probable or possible IFI; P¼0.024. Patients with second episodes
of IFI were not censored at the time of the second IFI.
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N¼149
1995–2001 2002–06 P
Median age (years, min.–max.) 59 (19–76) 60 (24–81) 0.195
Median duration of neutropenia (days, IQR) 22 (17–29) 21 (17–27) 0.612
Neutropenia 10 days (n/N, %) 60/64 (93.8%) 79/82 (96.3%) 0.699
Courses in patients with AML (n/N, %) 53/65 (81.5%) 63/84 (75.0%) 0.427
Treatment with high-dose AraC (n/N, %) 27/65 (41.5%) 26/84 (31.0%) 0.227
Courses with controlled disease before chemotherapy (n/N, %) 23/65 (35.4%) 32/84 (38.1%) 0.864
Courses with controlled disease after chemotherapy (n/N, %) 38/65 (58.5%) 56/84 (66.7%) 0.311
Systemic antifungal prophylaxis (n/N, %) 59/65 (90.8%) 69/84 (82.1%) 0.159
Incidence of IFI (n/N, %) 65/919 (7.1%) 84/774 (10.9%) 0.007
proven IFI 26/65 (40.0%) 16/84 (19.0%) 0.006
probable IFI 5/65 (7.7%) 27/84 (32.1%) ,0.001
possible IFI 34/65 (52.3%) 41/84 (48.8%) 0.742
IFI-related mortality (n/N, %) 37/65 (56.9%) 24/84 (28.6%) 0.001
Pathogens in proven IFI 0.063
Aspergillus spp. 11/26 (42.3%) 5/16 (31.3%)
Candida albicans 1/26 (3.8%) 3/16 (18.8%)
Candida non-albicans
a 8/26 (30.8%) 8/16 (50.0%)
Aspergillus spp.þCandida spp. 3/26 (11.5%) 0
Mucor sp. 1/26 (3.8%) 0
Blastoschizomyces capitatus 1/26 (3.8%) 0
B. capitatusþAspergillus spp. 1/26 (3.8%) 0
Reason for starting antifungal treatment 0.001
empirical (n/N, %) 22/65 (33.8%) 9/80 (11.3%)
deﬁnitive (n/N, %) 43/65 (66.2%) 71/80 (88.8%)
Median time to IFI treatment from date of IFI diagnosis (days, IQR) 0 (22 to 1) 0 (0–1) 0.047
Initial antifungal treatment
b (n/N,% )
amphotericin B 52/64 (81.3%) 57/84 (67.9%) 0.090
caspofungin 3/64 (4.7%) 10/84 (11.9%) 0.151
voriconazole 0 5/84 (6.0%) 0.070
itraconazole 3/64 (4.7%) 2/84 (2.4%) 0.652
ﬂuconazole 0 1/84 (1.2%) 1.000
liposomal amphotericin B 1/64 (1.6%) 0 0.432
combination therapy 5/64 (7.8%) 5/84 (6.0%) 0.746
no antifungal treatment 0 4/84 (4.8%) 0.134
Any antifungal treatment
b,c (n/N,% )
amphotericin B 61/64 (95.3%) 63/84 (75.0%) 0.001
caspofungin 8/64 (12.5%) 40/84 (47.6%) ,0.001
voriconazole 0 11/84 (13.1%) 0.003
itraconazole
d 11/63 (17.5%) 15/84 (17.9%) 1.000
ﬂuconazole
d 4/63 (6.3%) 2/84 (2.4%) 0.402
liposomal amphotericin B
d 12/63 (19.0%) 1/84 (1.2%) ,0.001
combination therapy
d 14/63 (22.2%) 15/84 (17.9%) 0.536
IQR, interquartile range; AraC, cytarabine.
aCandida glabrata in 10 courses, Candida tropicalis in 2 courses, Candida krusei in 2 courses, Candida guilliermondii in 1
course and Candida sp. in 1 course.
bIndependent of the duration of treatment; use of caspofungin in years before 2002 in clinical trials only.
cMultiple antifungal agents possible.
dAntifungal treatment was not completely evaluable in one course.
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JACwith IFI. In a study by Upton et al.
25 a similar evaluation was
undertaken, and risk factors for death and fungal infection-
attributable death were analysed. In contrast to our study,
they only examined patients with allogeneic SCT and showed
that a number of transplantation-related variables were associ-
ated with mortality. Allogeneic transplantations were not per-
formed at our centre and, thus, we determined a different
range of factors inﬂuencing survival in our patients. Interestingly,
in a subanalysis of the study of Upton et al.,
25 administration of
voriconazole was associated with a lower risk for death due to
invasive aspergillosis but not for all-cause mortality. Nivoix
et al.
26 analysed factors associated with overall mortality in
patients with cancer and invasive aspergillosis, and found an
improved OS in patients who received voriconazole as ﬁrst-line
therapy. Because, here, multivariate analysis was stratiﬁed by
ﬁrst-line antifungal therapy, voriconazole as an independent
prognostic factor for OS could not be analysed. Interestingly, in
this heterogeneous population, the authors also found that
the degree of certainty of diagnosis is an independent prognostic
factor, with an improved OS in patients with possible aspergillo-
sis. In contrast, in the study by Auberger et al.,
7 whose analysis
was similar to ours, only proven IFI was predictive for death in
a multivariate analysis. A possible reason why they could not
identify more risk factors might be the inhomogeneous popu-
lation analysed, including patients with intensive chemotherapy,
and autologous and allogeneic SCT.
Besides improved OS in patients with IFI, we also found a
decrease in IFI-related mortality from 56.9% to 28.6% in the
later period. The IFI-related mortality rate of 40.9% for the
whole observation period was similar compared with earlier
reports.
7,25,27,28 A reduction in IFI-related mortality was also
described in the recent literature,
7,8,25 despite a signiﬁcant
increase in the incidence of IFI,
7 comparing well with our
results. Our multivariate analysis showed a strong impact of
the use of novel antifungal agents on OS in patients with IFI,
independent of the inclusion of time period in the model. Thus,
improvement in therapeutic agents is probably the most impor-
tant cause for this ﬁnding.
29 An additional important factor most
likely to be associated with improved OS may be the earlier start
of antifungal treatment because of improved diagnostics. In the
later time period, newer diagnostic methods have been
implemented and the time period 2002–06 remained an inde-
pendent prognostic factor in our multivariate analysis, leading
us to assume a causal relationship. Unfortunately, in our study
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Figure 2. Overall survival (years) since start of chemotherapy in patients with IFI in the years 1995–2001 and 2002–06; HR¼0.535 (95% CI 0.363–
0.788), P¼0.001. Patients with second episodes of IFI were not censored at the time of the second IFI.
Table 3. Multivariate analysis in patients with IFI
HR 95% CI P
Controlled disease after chemotherapy 0.228 0.149–0.351 ,0.001
Certainty of IFI diagnosis (possible) 0.537 0.349–0.828 0.005
Age,60 years 0.583 0.392–0.869 0.008
Time period 2002–06 0.612 0.403–0.930 0.021
Use of novel antifungal agents 0.589 0.362–0.959 0.033
Controlled disease before chemotherapy 1.236 0.735–2.080 0.425
Certainty of IFI diagnosis (proven) 1.225 0.674–2.228 0.505
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improved diagnostics cannot be achieved, because the true
date of occurrence of IFI is unknown. Prospective studies are
needed to solve this question.
We found an overall incidence (based on courses of myelo-
suppressive chemotherapy) of 8.8% for IFI, which is within the
range reported in recent literature,
2,6,7 and a signiﬁcant differ-
ence for the rate of proven and probable IFI in the two time
periods, with less proven and more probable infections in years
2002–06. Improved diagnostics might at least partly explain
the increased detection rate of IFI. Interestingly, there was no
difference between the earlier and the later cohort in known
risk factors for IFI development,
1,30 such as the duration of neu-
tropenia, intensity of chemotherapy or the disease status before
or after chemotherapy, which could account for the increased
incidence of IFI. Also, the antimicrobial prophylaxis was not
changed for the whole observation period. Therefore, improved
diagnostics probably lead to an overall higher sensitivity of diag-
nosing IFI, but the actual incidence of IFI may not have been
changed. It is important to note that no major building works
were performed during the entire study period. The higher rate
of probable fungal infections might be attributable to the
routine use of the Aspergillus galactomannan antigen test and
PCR performed in BAL samples. Although PCR is not a microbio-
logical criterion in the 2002 IFI diagnosis criteria,
18 it is an impor-
tant tool in clinical practice for the early diagnosis of IFI and was
often positive in our study without further accepted microbiolo-
gical criteria. One should keep in mind that diagnosis of a prob-
able IFI was not based on PCR alone, but that a CT suspicious of
IFI was also present. If original EORTC criteria were applied, the
incidence of probable IFI in the period 2002–06 decreased to
17.9%, with a P value of 0.091, compared with the period
1995–2001 (7.7%). Possible IFI remained an independent prog-
nostic factor for improved OS in the multivariate analysis. Inter-
estingly, the difference in OS for certainty of diagnosis (Figure 1)
remained signiﬁcant too. The higher rate of proven infections in
the earlier years is possibly due to the fact that probable infec-
tions could not be detected early enough. After 2000, when
Aspergillus antigen was monitored twice weekly, a probable IFI
was assumed and treated before becoming a proven infection.
Another explanation might be that autopsies were less fre-
quently performed in the later years, as has been shown by
Donhuijsen et al.
8
In addition to an increase of mould infection, an increase in
candidaemia by non-albicans Candida species has been
reported.
31 Interestingly, Pagano et al.
2 found a pathogen
pattern similar to ours, as in their cohort 90% of mould infections
were Aspergillus species and 91% of yeast infections were
Candida species, with non-albicans species responsible for
.50% of the episodes of candidaemia. Similarly, in our cohort,
the rate of non-albicans Candida infections increased from 30%
in 1995–2001 to 50% in 2002–06. We would like to point out
that the rate of Candida infections did not differ between the
two time periods (13.8% of all IFIs in 1995–2001 versus
13.1% in 2002–06, P¼1.000) and, thus, the improved OS in
the later period was not caused by a higher rate of Candida
infections.
In conclusion, the results of our study show that the out-
comes of patients with IFI, i.e. IFI-related mortality and OS,
have improved signiﬁcantly in the past years. This is partly due
to the administration of novel antifungal agents. Other factors
improving OS were controlled underlying disease after che-
motherapy, possible IFI (in contrast to proven or probable IFI)
and age ,60 years.
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